Investor Presentaiton slide image

Investor Presentaiton

TLX591 differentiation Potential advantages with PSMA antibody approach Efficacy Potential for improved overall survival (OS) in advanced metastatic disease, with 40+ months OS reported to date1 For personal use only Patient comfort Reduced potential for off-target side-effects: dry eye, xerostomia (salivary gland ablation), back pain (ganglia irradiation) Patient-centric regimen Short treatment duration/significantly fewer hospital visits - two weeks total vs. 36 weeks, supports close supervision by medical oncology $ Cost effective Significantly lower 177 Lu isotope requirements with commensurate reduction in COGS, expected to also be available in "cold kit" format 1. Tagawa et al, Cancer 2019. Telix Pharmaceuticals Limited (ASX: TLX) 33 33 TELIX PHARMACEUTICALS
View entire presentation